ML signed the awaited deal for its inhaler drug last week. expect the announcement in a week.

Why ?

Its a pile of sh*te thats running out of cash .... AGAIN.

Dil I would of agreed with you for the last 5 years or longer. I am in for the recovery. They have restructured the whole company and we should see the rewards IMHO in the very near future. LOL

Before or after the next cash call ?

I take it you do not like this share now dil?

Hi Dill.
Choked but agree i am afraid cash call
seems on the cards see previous posts,
but sorry to say in to deep to dump
the crap, been a no brainer for years.
Looking at it fresh safe to say you would'nt
bet on it now on fundermentals.
But praying the tide has now turned with new
board - and hay if it does turn round held it
for so long, if there is a profit to be made pay
no tax now that would be a bonus doubt you agree
with me but i have to let it roll, stranger things have happened
still (fcuk) at present but ever hopefull.
regards
HUSTLER

Haven't for years Troys.

Good luck Hustler , you may get a spike on good news or something that may offer you an exit point but I wouldn't hold my breathe.

Some good news today. up 5%

Found a fiver in the tea tin did they ?

Hi dill
well there we have it latest spoof
now buying a profit making company quadrant
for 47 million in cash call for 26 mill
take it the smoke screen allows for a few million for wip
to stop them going bust this year
they must think we are a bunch of wank...
fear going to lose a bundle on this crap
suspect the tea lady nicked the teapot with the duke in it
as it was all that was worth nicking.

regards HUSTLER

Well i'm in profit. Down side from here on looks very slim.Upside looks very good to me.This is a new company now. LOL

ML Laboratories to buy Quadrant in 47m deal
By Michael Jivkov
17 June 2005


ML Laboratories confirmed yesterday it will acquire Quadrant Technologies, which develops and makes products for inhalers, for 47m.

The deal will double the size of the biotech and turn it into a profitable company. Quadrant was spun out of the Irish pharmaceuticals company Elan two years ago via a management buyout and registered a pre-tax profit of 1.3m last year.

According to City analysts, the combined company will generate net income of 8.5m before goodwill and amortisation in its first full year to September 2006. The tie-up will see ML focus on developing products for respiratory diseases. Quadrant, which makes powder drugs for inhalers, fits with ML's Innovata Biomed division which produces inhalers.

The biotech group also announced yesterday that it will buy out minority shareholders at Innovata Biomed, who hold 18.75 per cent of the company. The 1.85m transaction gives it full control of the unit. In an attempt to put its loss-making past behind it, ML plans to change its name to Innovata. It will relocate to Nottingham, where Quadrant is based.

ML shareholders hope that the acquisition will herald a turnaround at the company. Over the past decade the group has raised more than 120m from investors and paid nothing out. At the peak of its powers in 2000, ML was worth more than 1bn and its shares traded at more than 180p. They closed 1p higher at 21.75p yesterday.

Of the total 47m which ML plans to spend on buying Quadrant, 19.5m will be paid in cash. The company's broker, Code Securities, will raise this sum via a placing of 137 million new ML shares at 19p.

Another fine start today. Up we go

Troy , the downside for anyone buying is always 100%.

Dil and the upside unlimited

And heading up very nicely

Hi Troys
mm's will push it up some more to make
the issue at 19p look attractive,
i am hoping 30p plus b4 issue date asking a lot i know, then reduce part
of my stake still at a loss, but run the rest for
the long term hoping the new management is now genuine
as was not the case b4.
regards
HUSTLER

Spot on HUSTLER

I'm looking forward to picking up my tranch of the 19p Issue.

RNS Number:7759N
M.L. Laboratories PLC
20 June 2005
12:02

ML Laboratories PLC

New Licensing Agreement with Maxygen and Grant of US Patent for
Gene Expression Technology


St Albans, UK, 20 June 2005 -- ML Laboratories PLC (LSE: MLB) today announces
that Maxygen Inc has signed a commercial licence agreement for ML's UCOE
(Ubiquitous Chromatin Opening Element) gene expression technology.

ML also announces that the US Patent and Trademark Office has issued to ML a
second US patent for UCOE.

UCOEs improve the yield, consistency and stability of protein production in
cultured mammalian cells, allowing simpler and quicker generation of proteins at small scale for drug discovery, as well as quicker and easier isolation of
stable, highly productive cell lines suitable for larger-scale manufacture of
protein therapeutics. Further applications of the technology include gene
therapy, transgenics and generation of cell lines for drug screening.

ML has already licensed UCOEs to a number of pharmaceutical and biotechnology
companies in North America, Europe and Japan.

Licence Agreement with Maxygen

Based in Redwood City, California, Maxygen develops superior versions of
existing protein pharmaceuticals. Maxygen's technologies combine molecular
biology and protein modification to create novel biotechnology products.

In February 2003, Maxygen signed a research licence to ML's UCOE technology.
The licence agreement announced today allows Maxygen to use the technology for
the development and commercialization of its portfolio of therapeutic proteins.
The financial terms were not disclosed.

Grant of Second US Patent

The second patent (US6881556) awarded to ML for UCOE covers the use of DNA
elements that enhance the efficiency of protein production in mammalian cells by prevention of gene silencing. The original broad US patent (US6689606) was
issued in 2004.

Kieran Murphy, Chief Executive Officer of ML Laboratories, commented:

"The agreement with Maxygen and the granting of our second US patent for UCOE
are further validations of the value of this proprietary platform. UCOEs
represents an exciting opportunity and we believe that the developments
announced today will strengthen our offering as we seek to divest non-core
assets as part of the ongoing restructuring process."

Discussions regarding the divestment of non-core assets are currently
progressing.

The price has ticked up nicely on that news.